Gilead Sciences (NASDAQ:GILD) Lifted to “Outperform” at Raymond James

Raymond James upgraded shares of Gilead Sciences (NASDAQ:GILD) from a market perform rating to an outperform rating in a research note released on Monday, Marketbeat.com reports. They currently have $93.00 target price on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the company. Royal Bank of Canada reissued a sector perform rating and set a $74.00 target price on shares of Gilead Sciences in a research note on Monday, July 1st. Oppenheimer reaffirmed an outperform rating and issued a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Morgan Stanley dropped their price objective on Gilead Sciences from $80.00 to $78.00 and set an equal weight rating for the company in a research note on Friday, April 26th. Needham & Company LLC reaffirmed a hold rating on shares of Gilead Sciences in a research note on Friday, April 26th. Finally, StockNews.com raised Gilead Sciences from a buy rating to a strong-buy rating in a research note on Saturday, April 27th. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of Hold and a consensus price target of $84.00.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $68.75 on Monday. The company has a market cap of $85.65 billion, a price-to-earnings ratio of 190.97, a price-to-earnings-growth ratio of 2.87 and a beta of 0.18. The stock has a 50 day simple moving average of $66.23 and a 200-day simple moving average of $71.88. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $87.86. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.37 EPS. On average, equities analysts forecast that Gilead Sciences will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.48%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.29% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Schonfeld Strategic Advisors LLC purchased a new position in Gilead Sciences in the third quarter valued at about $896,000. Integrated Wealth Concepts LLC raised its position in Gilead Sciences by 1.2% in the third quarter. Integrated Wealth Concepts LLC now owns 28,215 shares of the biopharmaceutical company’s stock valued at $2,114,000 after purchasing an additional 338 shares during the period. Creative Planning raised its position in Gilead Sciences by 0.5% in the third quarter. Creative Planning now owns 152,961 shares of the biopharmaceutical company’s stock valued at $11,463,000 after purchasing an additional 767 shares during the period. Integrated Advisors Network LLC raised its position in Gilead Sciences by 1.7% in the third quarter. Integrated Advisors Network LLC now owns 14,543 shares of the biopharmaceutical company’s stock valued at $1,090,000 after purchasing an additional 238 shares during the period. Finally, Tompkins Financial Corp raised its position in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.